Intensive early HIV treatment in newborns to aim for remission
Treatments studied
Part of Immune system & allergy, Infections clinical trials.
This study gives very early, intensive HIV medicine to infants diagnosed with HIV and follows them closely to see if HIV can go into remission (stop being detectable without ongoing treatment). It may help families understand whether treating right after birth can change a child’s long-term HIV outlook.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Babies must start the study within 48 hours after birth.
- The baby must be born at 37 weeks or later and weigh at least 2 kilograms.
- The mother must have HIV infection around pregnancy (either suspected at delivery or confirmed by blood tests).
- The baby must be able to take HIV medicine by mouth or feeding tube.
- The mother must agree (give consent) for the baby’s participation in the study steps.
- The family must be able to follow frequent clinic visits and testing schedules for months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares new HIV medicines to help children and teens who have HIV and are either starting treatment or whose current treatment isn't working. The goal is to find better ways to control the virus and keep kids healthy.
This study tests whether giving a combination of two lab-made antibodies (PGT121.414.LS and VRC07-523LS) to newborns exposed to HIV during pregnancy is safe and how the body processes them. It may help protect infants from getting HIV after birth.
This study looks at whether two HIV medicines given as injections every 4 weeks—cabotegravir and rilpivirine—are safe and effective for pregnant women with HIV who have an undetectable viral load. The goal is to help pregnant people with HIV stay healthy and reduce the risk of passing HIV to their baby.
This study checks how safe and well two HIV medicines work in children ages 6 to under 12. It also measures drug levels in the body to guide dosing and watch for side effects.
This study looks at ways to test and treat newborns for HIV early to improve their long-term health. It is for mothers with HIV whose babies are less than 3 days old and who are willing to have their babies tested and followed at home.
This trial tests whether giving early neutralizing antibodies can help infants living with HIV control the virus better. It aims to improve their long-term health.
Hear when a new HIV Infection trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.